D50.9 Insurance Policy Changes

ICD-10 D50.9 is officially defined as "Iron deficiency anemia, unspecified." code D50.9 is referenced in 9 tracked payer policy changes from UnitedHealthcare, Independence Blue Cross, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D50.9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

UnitedHealthcare · Effective Dec 1, 2026Medium impact
Intravenous Iron Replacement Therapy (Feraheme ® , Injectafer ® , & Monoferric ® )
UnitedHealthcare Community Plan of Indiana revised its Medicaid medical policy for Feraheme (ferumoxytol), Injectafer (ferric carboxymaltose), and Monoferric (ferric derisomaltose). Coverage is now described as proven for iron deficiency anemia without CKD and for iron deficiency anemia with CKD but without ESRD, and Injectafer is covered for iron deficiency in adults with NYHA class II/III heart failure to improve exercise capacity when all listed criteria are met; the policy also adds definitions and ICD-10 codes for these indications and removes the language excluding Indiana.
Independence Blue Cross · Effective Mar 23, 2026Medium impact
MA08.150a, Intravenous (IV) Iron Preparations
Independence Blue Cross Medicare Advantage policy MA08.150b (effective 03/23/2026) supersedes MA08.150a with new coverage criteria for IV iron in pediatric patients and expanded ICD-10 diagnosis codes including pregnancy-related anemia (O99.011-O99.013, O99.019, O99.02, O99.03) and chemotherapy-induced anemia (D64.81). The policy maintains preferred vs. nonpreferred product tiering for adults 18+ and excludes preferred product requirements for patients under 18 and pregnant individuals.
Independence Blue Cross · Effective Mar 23, 2026Medium impact
MA08.150a, Intravenous (IV) Iron Preparations
Independence Blue Cross updated MA08.150a to MA08.150b, adding new coverage criteria for pediatric IV iron use and expanding ICD-10 diagnosis codes to include pregnancy-related anemias (O99.011-O99.019, O99.02, O99.03) and chemotherapy-induced anemia (D64.81). The policy maintains preferred vs. nonpreferred product designations with specific coverage rules based on prior treatment history and contraindication documentation.
Independence Blue Cross · Effective Mar 23, 2026Medium impact
08.02.29a, Intravenous (IV) Iron Preparations
Independence Blue Cross updated policy 08.02.29a to 08.02.29b, adding new coverage criteria for pediatric IV iron preparations, expanding ICD-10 diagnosis codes to include pregnancy-related anemia and heart failure conditions, and clarifying preferred vs. nonpreferred product designations. Billing teams must implement these expanded diagnosis codes and ensure claims reflect the new clinical criteria effective March 23, 2026.
Independence Blue Cross · Effective Mar 23, 2026Medium impact
08.02.29a, Intravenous (IV) Iron Preparations
Independence Blue Cross updated IV Iron Preparations policy (08.02.29b, effective 03/23/2026) to add new coverage criteria for pediatric patients and expand ICD-10 diagnosis codes to include pregnancy-related anemias, anemia in neoplastic disease, chemotherapy-induced anemia, and heart failure. The preferred product hierarchy remains unchanged for adults, but new clinical scenarios now have defined coverage pathways.
Aetna · Identified Oct 5, 2026Medium impact
Lead Testing (CPB 0553, reviewed 2026-08-28)
Aetna considers blood lead testing medically necessary for diagnosis of persons with signs and symptoms of lead poisoning and for pregnant or lactating women who have any listed lead exposure risk factor. Lead screening is covered for persons with occupational lead exposure and, as a preventive service, for children in listed high-risk groups. Measurement of lead in bone, hair, teeth, or urine is considered experimental, investigational, or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Intravenous Iron Therapy (CPB 0575, reviewed 2026-07-01)
Feraheme, Ferrlecit, Injectafer, Monoferric and Venofer are medically necessary only for commercial members who have a contraindication, intolerance or ineffective response to the lower cost alternatives generic ferumoxytol, generic iron sucrose, generic sodium ferric gluconate and INFeD (iron dextran) for the labeled indication. Precertification is required for Feraheme, Ferrlecit, generic sodium ferric gluconate, Injectafer, Monoferric, Venofer and generic iron sucrose in applicable plan designs. Intravenous iron is considered experimental, investigational or unproven for other indications, including acute mountain sickness and anemia of inflammation, and it is contraindicated for genetic hemochromatosis or hemochromatosis secondary to iron overload.
Aetna · Identified Aug 14, 2026Medium impact
Double Balloon Enteroscopy (CPB 0737, reviewed 2025-11-13)
Aetna considers double balloon enteroscopy medically necessary for dilation of small bowel strictures in Crohn's disease, evaluating suspected small bowel malignancies, evaluating the colon after incomplete colonoscopy, suspected Meckel's diverticulum with an indefinite imaging work-up, obscure GI bleeding with objective evidence of recurrent bleeding, removing entrapped foreign bodies in the small bowel, removing large polyps greater than 10 mm in Peutz-Jeghers syndrome, GI bleeding when the small intestine is the source, and use with ERCP in individuals with surgically altered upper GI anatomy. Aetna considers double balloon enteroscopy experimental, investigational or unproven for other indications, including detection of small bowel neuroendocrine tumors, small bowel varices, treatment of intussusception, treatment of angioectasia (type 1 small bowel vascular lesions), and treatment of post-operative bile leakage after hepaticojejunostomy. Combined double balloon enteroscopy and endoscopic ultrasound for evaluation of Crohn's disease is also considered experimental, investigational or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders
Wireless capsule endoscopy of the small bowel is medically necessary for suspected small bowel bleeding after prior inconclusive upper and lower GI endoscopic studies performed during the current episode of illness, for initial diagnosis of suspected Crohn disease without evidence of disease on small bowel follow-through and upper and lower endoscopy, for an established Crohn disease diagnosis when there are unexpected changes in disease course or response to treatment, and for small bowel surveillance in hereditary GI polyposis syndromes including familial adenomatous polyposis and Peutz-Jeghers syndrome. Other uses are investigational, including evaluating the extent of known Crohn disease or ulcerative colitis, the esophagus, the colon including colonic polyps or colon cancer, other GI diseases not presenting with GI bleeding, initial evaluation of acute upper GI bleeding, lower GI bleeding with major risks for colonoscopy, and patients following an incomplete colonoscopy. The patency capsule is investigational, and magnetic capsule endoscopy is investigational for unexplained upper abdominal complaints and all other indications.

Watch D50.9

Get one email when a payer policy names D50.9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code D50.9?

There are 9 tracked policy changes affecting code D50.9, including updates from UnitedHealthcare, Independence Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D50.9?

Payers that have issued tracked updates for code D50.9 include: UnitedHealthcare, Independence Blue Cross, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code D50.9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D50.9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D50.9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Intravenous Iron Replacement Therapy (Feraheme ® , Injectafer ® , & Monoferric ® )

MA08.150a, Intravenous (IV) Iron Preparations

MA08.150a, Intravenous (IV) Iron Preparations

08.02.29a, Intravenous (IV) Iron Preparations

08.02.29a, Intravenous (IV) Iron Preparations

Lead Testing (CPB 0553, reviewed 2026-08-28)

Intravenous Iron Therapy (CPB 0575, reviewed 2026-07-01)

Double Balloon Enteroscopy (CPB 0737, reviewed 2025-11-13)

Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders

What insurance policy changes affect code D50.9?

Which payers have updated policy for code D50.9?

How do I get notified when code D50.9 policy changes?

Why do payers change policies for code D50.9?